Reliance (NYSE:RS – Get Free Report) and BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) are both industrials companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.
Earnings and Valuation
This table compares Reliance and BioNexus Gene Lab”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Reliance | $14.29 billion | 1.45 | $739.40 million | $17.20 | 23.65 |
| BioNexus Gene Lab | $7.43 million | 0.50 | -$2.98 million | ($1.26) | -1.00 |
Analyst Recommendations
This is a breakdown of current recommendations for Reliance and BioNexus Gene Lab, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Reliance | 1 | 6 | 2 | 1 | 2.30 |
| BioNexus Gene Lab | 1 | 0 | 0 | 0 | 1.00 |
Reliance presently has a consensus price target of $387.43, suggesting a potential downside of 4.75%. Given Reliance’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Reliance is more favorable than BioNexus Gene Lab.
Risk and Volatility
Reliance has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, BioNexus Gene Lab has a beta of 4.22, indicating that its share price is 322% more volatile than the S&P 500.
Insider & Institutional Ownership
79.3% of Reliance shares are held by institutional investors. Comparatively, 18.9% of BioNexus Gene Lab shares are held by institutional investors. 0.4% of Reliance shares are held by company insiders. Comparatively, 0.1% of BioNexus Gene Lab shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Reliance and BioNexus Gene Lab’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Reliance | 5.65% | 12.51% | 8.47% |
| BioNexus Gene Lab | -82.38% | -32.92% | -29.75% |
Summary
Reliance beats BioNexus Gene Lab on 14 of the 15 factors compared between the two stocks.
About Reliance
Reliance, Inc. operates as a diversified metal solutions provider and the metals service center company in the United States, Canada, and internationally. The company distributes a line of approximately 100,000 metal products, including alloy, aluminum, brass, copper, carbon steel, stainless steel, titanium, and specialty steel products; and provides metals processing services to general manufacturing, non-residential construction, transportation, aerospace, energy, electronics and semiconductor fabrication, and heavy industries. It sells its products directly to original equipment manufacturers, which primarily include small machine shops and fabricators. The company was formerly known as Reliance Steel & Aluminum Co. and changed its name to Reliance, Inc. in February 2024. Reliance, Inc. was founded in 1939 and is based in Scottsdale, Arizona.
About BioNexus Gene Lab
BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Receive News & Ratings for Reliance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reliance and related companies with MarketBeat.com's FREE daily email newsletter.
